Evidence map›Paper›PMID 41887927›Full record

ArticleExpert opinion on drug discovery2026

The impact of antisense oligonucleotide (ASO) therapeutics on the future of rare disease drug discovery.

Ruchi Ruchi, Kriti Gupta, Rajkumar Verma, José Manautou, Xiao-Bo Zhong, Raman Bahal

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert opinion on drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ruchi RuchiDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT, USA.
Kriti GuptaDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT, USA.
Rajkumar VermaDepartment of Neuroscience, School of Medicine, University of Connecticut (UConn Health), Farmington, CT, USA.
José ManautouDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT, USA.
Xiao-Bo ZhongDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT, USA.
Raman BahalDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT, USA.

Funding

Developing next-generation RNA inhibitors for stroke therapyR01NS140176 · NINDS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI Raman Bahal, Rajkumar Verma · 2025 to 2026
$1.0M
Next generation gamma Peptide Nucleic Acids (yPNAs) for the treatment of ischemic strokeR21NS114981 · NINDS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI VERMA, RAJKUMAR · 2020 to 2020
$464k
NINDS NIH HHS R01 NS140176NINDS NIH HHS R21 NS114981
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antisense oligonucleotide (ASO)FDA-approved ASOsnucleic acid therapeuticsrare disease

Identifiers

PMID41887927
PMCPMC13292031

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.